UNSPSC 51382903: Tesimide

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C16H15NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WHO633E898, chemically known as 1,3(2h,4h)-isoquinolinedione, 5,6,7, 8-tetrahydro-4-(phenylmethylene)- but generally known as tesimide, which bears US NIH Compound Identifier 5384729. European Medicines Agency schedules Tesimide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10935MIG.

UNSPSC 51382903 Tesimide, a Commodity code, does not align with the state and local procurement activity tagged under it. The recent opportunities record shows three solicitations for naloxone, safe drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and over-the-counter products—none of which are tesimide or tesimide-related compounds. The mismatch suggests either a classification error in the opportunities database or that tesimide procurement activity does not currently appear in state and local competitive solicitations at scale sufficient to populate this code's record.

The issuing bodies across the three opportunities span diverse jurisdictions: Seminole County, Florida (a county health department procurement), the Texas Health and Human Services Commission (a state health agency), and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), a multi-state cooperative vehicle administered by Minnesota's Department of Administration. The geographic spread includes Florida, Texas, and Minnesota, with MMCAP's cooperative model extending procurement reach across participating jurisdictions including Oregon. Activity intensity is light—only three opportunities in the recent record, posted between January and June 2026, with no repeat buyers under tesimide or closely related pharmaceutical compounds. Seminole County issued an IFB for naloxone and drug deactivation systems with a response deadline of July 26, 2023; Texas HHS issued an RFI on March 27, 2026, with a response deadline of April 3, 2026, to explore direct-to-manufacturer prescription models; and MMCAP issued an RFP on January 20, 2026, with questions due February 18, 2026, and proposals due March 26, 2026, for generic multi-source pharmaceuticals and OTC products. The code shows little relevant recent activity and warrants clarification against actual pharmaceutical procurement drivers before committing pursuit resources.